SEM's $16.50 Take-Private Moment: Undervalued or Perfectly Timed?

Wednesday, Mar 4, 2026 10:08 am ET2min read
SEM--
Aime RobotAime Summary

- Select Medical HoldingsSEM-- plans to go private in a $3.9B deal led by executives and Welsh, Carson, Anderson & Stowe, driving shares up 8.4%.

- Shareholders will receive $16.50 per share, a 10% premium to March 2026 prices but below the $17.70 analyst average target.

- The move aims to provide operational flexibility amid healthcare industry861075-- challenges like reimbursement pressures and cost volatility.

- Despite a 11.1% YoY EPS drop in Q4 2025, the company’s $1.86B market cap reflects ongoing strategic shifts.

Select Medical Holdings Corporation SEM surged 8.4% yesterday after unveiling plans to go private. The company will be acquired by a group led by Executive Chairman and Co-Founder Robert Ortenzio, Senior EVP Martin Jackson, and private equity firm Welsh, Carson, Anderson & Stowe, in a transaction that values the entire enterprise at $3.9 billion.

Shareholders will receive $16.50 per share in cash, reflecting a 10% premium to the March 2, 2026, closing price and an 18% premium to the Nov. 24, 2025, level. Still, the offer sits below the average analyst target of $17.70, suggesting some investors may see additional upside. The spread between the high target of $21 and the low target of $16 reflects different risk views, but the consensus direction remains positive.

The current management is likely to remain in place following the completion of the deal during mid-2026. At the end of 2025, Select MedicalSEM-- operated across 39 states and the District of Columbia, focusing on critical illness recovery and rehabilitation services. The company reported fourth-quarter 2025 adjusted EPS of 16 cents, down 11.1% year over year, while net operating revenues rose 6.4% to $1.4 billion. It currently has a market cap of $1.86 billion.

The transaction moves Select Medical into private hands at a time when healthcare providers are grappling with reimbursement pressure and cost volatility. Operating outside the public market spotlight could give management greater flexibility to streamline operations, reshape its portfolio and pursue longer-term strategic goals.

A Look at UHS and THC in a High-Cost Environment

Peers are navigating similar headwinds. Universal Health Services, Inc. UHS faced lower-than-expected admissions and higher operating costs in the fourth quarter of 2025, though higher revenue per adjusted admission provided some relief. UHS projects 2026 EPS of $22.64-$24.52, with the midpoint indicating 8.5% growth from 2025.

Tenet Healthcare Corporation THC benefited from stronger same-facility revenues, improved acuity and a favorable payer mix in the fourth quarter, supported by facility buyouts in its Ambulatory Care segment. However, rising operating expenses weighed on results. Tenet expects a 2026 adjusted EBITDA margin of 20.9-21.5%, with the midpoint slightly below the 2025 level of 21.4%.

SEM’s Price Performance & Valuation

Shares of Select Medical have declined 9.9% over the past year, underperforming the broader industry and the S&P 500 Index.

SEM Price Performance

Zacks Investment Research Image Source: Zacks Investment Research

From a valuation standpoint, Select Medical trades at a forward price-to-earnings ratio of 12.31X, higher than the industry average of 11.77X. Yet it carries a Value Score of A.

Zacks Investment Research Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Select Medical’s 2026 earnings implies a 10.3% rise year over year, followed by 17.9% growth next year.

Zacks Investment Research Image Source: Zacks Investment Research

The stock currently carries a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Free Report: Profiting from the 2nd Wave of AI Explosion

The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.

Investors who bought shares like Nvidia at the right time have had a shot at huge gains.

But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.

Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.

Access AI Boom 2.0 now, absolutely free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report



Universal Health Services, Inc. (UHS): Free Stock Analysis Report

Tenet Healthcare Corporation (THC): Free Stock Analysis Report

Select Medical Holdings Corporation (SEM): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet